Direct-to-consumer marketing of stem cell interventions by Canadian businesses
- PMID: 30255734
- DOI: 10.2217/rme-2018-0033
Direct-to-consumer marketing of stem cell interventions by Canadian businesses
Abstract
Aim: This study examines marketing claims of Canadian businesses engaged in direct-to-consumer advertising of putative stem cell treatments.
Methods: Internet searches were used to locate Canadian businesses selling stem cell interventions. Company websites were subjected to detailed analysis.
Results: In total, 30 Canadian businesses sell stem cell interventions provided at 43 clinics. Autologous stem cells are the most common types of products promoted by such businesses. Company websites minimize risks while making strong claims about benefits of stem cell interventions.
Discussion: Businesses' representations could result in patients making health-related decisions informed by marketing claims rather than best available scientific evidence.
Conclusion: Although there is absent development of new regulations and guidance, the Canadian direct-to-consumer marketplace for stem cell interventions appears poised for expansion.
Keywords: Canada; Health Canada; clinics; direct-to-consumer marketing; empirical analysis; physicians; stem cells.
Similar articles
-
The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.Perspect Biol Med. 2018;61(1):7-24. doi: 10.1353/pbm.2018.0024. Perspect Biol Med. 2018. PMID: 29805145 Review.
-
Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies.Regen Med. 2023 Nov;18(11):857-868. doi: 10.2217/rme-2023-0117. Epub 2023 Oct 23. Regen Med. 2023. PMID: 37867326
-
Beyond "medical tourism": Canadian companies marketing medical travel.Global Health. 2012 Jun 15;8:16. doi: 10.1186/1744-8603-8-16. Global Health. 2012. PMID: 22703873 Free PMC article.
-
US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era.Cytotherapy. 2024 Apr;26(4):393-403. doi: 10.1016/j.jcyt.2024.01.001. Epub 2024 Feb 8. Cytotherapy. 2024. PMID: 38340106
-
Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine.Cell Stem Cell. 2008 Dec 4;3(6):591-4. doi: 10.1016/j.stem.2008.11.001. Cell Stem Cell. 2008. PMID: 19041775 Review.
Cited by
-
Regenerative medicine in Obstetrics & Gynecology: Current status under the Act on the Safety of Regenerative Medicine in Japan.Regen Ther. 2024 Aug 13;26:564-570. doi: 10.1016/j.reth.2024.08.003. eCollection 2024 Jun. Regen Ther. 2024. PMID: 39228904 Free PMC article. Review.
-
On Patient Safety: Regenerative Medicine-The Hype Amplifies Safety Concerns.Clin Orthop Relat Res. 2019 Jul;477(7):1566-1568. doi: 10.1097/CORR.0000000000000832. Clin Orthop Relat Res. 2019. PMID: 31169627 Free PMC article. No abstract available.
-
Closing gaps, opening doors: an experimental collaboration in stem cell intervention.Mol Biol Rep. 2020 May;47(5):4105-4108. doi: 10.1007/s11033-020-05469-5. Epub 2020 May 6. Mol Biol Rep. 2020. PMID: 32372173 Free PMC article.
-
Looking into the future: Gene and cell therapies for glaucoma.Vet Ophthalmol. 2021 Mar;24 Suppl 1(Suppl 1):16-33. doi: 10.1111/vop.12858. Epub 2021 Jan 7. Vet Ophthalmol. 2021. PMID: 33411993 Free PMC article. Review.
-
Ethical development of stem-cell-based interventions.Nat Med. 2019 Jul;25(7):1037-1044. doi: 10.1038/s41591-019-0511-6. Epub 2019 Jul 3. Nat Med. 2019. PMID: 31270501 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous